Clinical Trial Update: A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for GTX-102 in Angelman Syndrome, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angelman Syndrome

Drugs mentioned

• GTX-102

Snippet

Sponsor: Ultragenyx Pharmaceutical Inc | Conditions: Angelman Syndrome | Phase 2 | Status: RECRUITING